New Stock News | Chenyi Biologicals' Hong Kong IPO Prospectus Invalid

Chengyi Bioscience Cayman Limited (referred to as "Chengyi Bioscience") submitted its Hong Kong IPO prospectus on October 8, 2025, valid for 6 months until April 8, 2026, with Jefferies, BofA Securities, and CICC as its joint sponsors. According to the previous prospectus, Chengyi Bioscience is a global biotechnology company in the clinical stage, dedicated to exploring and developing a new generation of oral small molecule drugs to address significant unmet medical needs in the global cardiovascular metabolism and inflammatory disease areas. The company leverages its proprietary TRANDD platform, with a product pipeline tailored for both monotherapy and combination therapy, aiming to achieve effective results in weight management (obesity/overweight), metabolic associated fatty liver disease ("MASH"), osteoarthritis ("OA") pain, and other cardiovascular metabolic diseases.